04/22/2022 Edition 60
----- Division of Research -----
Aging and Health Disparities

This FOA will support institutional training programs for predoctoral and postdoctoral level researchers with diverse educational backgrounds (i.e., basic biology, translational and clinical research, data science and behavioral research). The program invites eligible institutions to develop interdisciplinary training programs that will provide trainees with the knowledge and skills in data science, disease biology, and traditional and emerging drug discovery disciplines necessary to conduct rigorous and cutting-edge basic, translational, and clinical research for AD and AD-related dementias.

NIH/NIAAA Specialized Alcohol Research Centers (P50 Clinical Trial Optional), RFA-AA-22-001 Application Due Date: November 15, 2022 Up to $1.15M per year up to 5 years

FOA to foster and conduct interdisciplinary, collaborative research on Alcohol Use Disorder (AUD), alcohol misuse and alcohol related problems, and other health related consequences across the lifespan. The NIAAA Centers Program provides leadership in research, and research methodology development on a wide variety of topics relevant to the Institute’s mission. Topics include, but are not limited to, the nature, etiology, genetics, diagnosis, treatment, and prevention of AUD, alcohol-related end organ diseases and their biomedical, psychosocial, and economic consequences across the lifespan and racial/ethnic groups and other health disparity populations. Centers are also major contributors to the development of research methods, technologies, and approaches that sustain innovative goal-directed research.

Socio-Economic
Arnold Ventures Demonstrating the Power of Evidence-Based Programs to "Move the Needle" on Major U.S. Social Problems Submission Deadline: No deadline for submitting a letter of interest. Within one month, they will respond to let you know if they are interested in receiving a full proposal. $1,000,000 to $5,000,000

A central goal of U.S. evidence-based policy reform is to focus government and philanthropic funding on social programs and practices ("interventions") that have credible evidence of meaningful positive effects on people's lives. The imperative for doing so is clear: Most social interventions are unfortunately found not to produce the hoped-for effects when rigorously evaluated - a pattern that occurs not just in social spending but in other fields, such as medicine and business. Thus, without a strong focus on evidence-based interventions, it is hard to see how social spending can successfully address poverty, educational failure, violence, drug abuse, and other critical U.S. problems.

Fortunately, there are some social interventions that have been rigorously shown to improve important life outcomes. While relatively few in number, their strong evidence of sizable effects suggests that, if expanded, they offer a path to meaningful progress that spending-as-usual cannot.

The Laura and John Arnold Foundation's (LJAF) Moving the Needle initiative seeks to spur expanded implementation of such interventions in order to make significant headway against U.S. social problems. Specifically, the initiative is designed to encourage state or local jurisdictions, or other entities, to:

  1. Adopt social interventions shown in well-conducted randomized controlled trials (RCTs) to produce large, sustained effects on important life outcomes;
  2. Implement these interventions on a sizable scale with close adherence to their key features; and
  3. Determine, through a replication RCT, whether the large effects found in prior research are successfully reproduced so as to move the needle on important social problems.

USAID Annual Program Statement for Development Innovation Ventures, #7200AA22APS00001 Application Deadline: Accepted on a rolling basis until 10/31/2022 $25,000 to $15,000,000

Through a year-round grant competition, Development Innovation Ventures (DIV) sources proposals for innovations that address international development challenges and improve the lives of people living in poverty in developing countries around the world. DIV provides tiered funding to pilot, test, and transition to scale (i.e., grow to reach the highest number of beneficiaries possible) those innovations that demonstrate evidence of impact, cost-effectiveness, and the potential to scale.

DIV funds four types of grants. Stage 1, Stage 2, and Stage 3 grants follow a tiered approach that aligns the funding amount to the strength of the evidence of impact, cost-effectiveness, and scalability of the proposed innovation. Evidence Generation grants are reserved for rigorous evaluations of already scaled or scaling development solutions that lack sufficient rigorous evidence of impact and cost-effectiveness.

DIV takes a portfolio approach to impact, meaning it takes relatively small, high-risk bets on early-stage innovations that may generate varying levels of impact as they are piloted and invests larger amounts of money in later-stage innovations that are better able to demonstrate impact, thereby maximizing the social impact of the overall portfolio. DIV is deliberately open to all kinds of innovations and all forms of innovators, in all sectors and countries in which USAID operates. Ultimately, DIV aims to help transition the best innovations with proven impact to scale to improve the lives of millions of people around the world.

Neurosciences

The purpose of the FOA is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS) (note: only prospective observational studies will be considered). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.

Addictions

Avenir means future in French, and this Avenir Award Program looks toward the future by supporting early stage investigators proposing highly innovative research in the area of chemistry and pharmacology of substance use disorders and addiction. The purpose of this award is to support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field.


This FOA will support the development and testing of enhanced models of care that are able to optimally integrate HIV, addiction, and primary care services.

NIDA is interested in research that addresses gaps related to the delivery of comprehensive, integrated health services to include the full continuum of HIV/AIDS services, addiction prevention and treatment services, and primary care services, with a goal of improving the coordination of care, and improving health outcomes related to HIV and SUD in the US.

Federal
View current federal funding opportunities (pdf) 04/15/2022 curated by our Van Scoyoc partnership.
Althea Sheets, [email protected]u, 702-895-1880
Research, Scholarly, and Creative Activities Development Manager
Office of Sponsored Programs